The rapid evolution of cell and gene therapies (CGTs) offers life-changing and potentially curative outcomes but also creates significant challenges for healthcare systems worldwide. The complexity, production costs, and long-term value assessment of these therapies require new economic and reimbursement frameworks. This session will explore value-based pricing, outcome-linked payment models, and the integration of real-world evidence to support sustainable market access. Experts in healthcare economics, policy, and market strategy will discuss innovative reimbursement solutions that balance patient access, affordability, reduce burden on the healthcare systems, and promote continued innovation in the CGT ecosystem.